Demographics across trials
| . | All Patients . | CD19 . | CD22 . | CD19/CD22 . | P . |
|---|---|---|---|---|---|
| All patients | n = 134 | n = 50 | n = 68 | n = 16 | n/a |
| Demographics | |||||
| Median age∗, (IQR) | 15.2 (9.4-21.2) | 13.5 (8.6-18.8) | 15.8 (9.5-21.1) | 20.5 (16.2-28.3) | .02 |
| Sex, male, n (%) | 97 (72.3%) | 41 (82%) | 44 (64.7%) | 12 (75%) | .11 |
| Ethnicity, non-Hispanic, n (%) | 94 (70.1%) | 31 (62%) | 52 (76.5%) | 11 (68.8%) | .23 |
| Race, White†, n (%) | 96 (80.7%) | 36 (80%) | 52 (82.5%) | 8 (72.7%) | .74 |
| Prior therapy | |||||
| Median number of prior cycles of therapy not including HSCT (IQR) | 5 (3-6) | 4 (2-5) | 6 (4-7) | 4.5 (3-7) | .0002 |
| Prior HSCT, n (%) | 76 (56.7%) | 22 (44%) | 44 (64.7%) | 10 (62.5%) | .071 |
| Prior CAR, n (%) | 54 (40.3%) | 2 (4%) | 45 (66.2%) | 7 (43.8%) | <.0001 |
| Prior blinatumomab, n (%) | 44 (32.8%) | 4 (8%) | 28 (41.2%) | 12 (75%) | <.0001 |
| Prior inotuzumab, n (%) | 23 (17.2%) | 0 | 18 (26.5%) | 5 (31.3%) | .0002 |
| Disease status‡ | |||||
| No. of pts with ≥M2 marrow, % | 91 (67.9%) | 31 (62%) | 52 (76.5%) | 8 (50%) | .066 |
| No. of pts with CNS2+, % | 7 (5.2%) | 5 (10%) | 2 (2.9%) | 0 | .15 |
| No. of pts with EM§ disease, % | 24 (17.9%) | 4 (8%) | 12 (17.6%) | 8 (50%) | .0007 |
| Disease response‖ | |||||
| No. of pts with CR, % | 88 (66.2%) | 31 (62%) | 49 (73.1%) | 8 (50%) | .16 |
| No. of pts with MRD-neg CR, % | 77 (58.3%) | 27 (54%) | 42 (63.6%) | 8 (50%) | .45 |
| . | All Patients . | CD19 . | CD22 . | CD19/CD22 . | P . |
|---|---|---|---|---|---|
| All patients | n = 134 | n = 50 | n = 68 | n = 16 | n/a |
| Demographics | |||||
| Median age∗, (IQR) | 15.2 (9.4-21.2) | 13.5 (8.6-18.8) | 15.8 (9.5-21.1) | 20.5 (16.2-28.3) | .02 |
| Sex, male, n (%) | 97 (72.3%) | 41 (82%) | 44 (64.7%) | 12 (75%) | .11 |
| Ethnicity, non-Hispanic, n (%) | 94 (70.1%) | 31 (62%) | 52 (76.5%) | 11 (68.8%) | .23 |
| Race, White†, n (%) | 96 (80.7%) | 36 (80%) | 52 (82.5%) | 8 (72.7%) | .74 |
| Prior therapy | |||||
| Median number of prior cycles of therapy not including HSCT (IQR) | 5 (3-6) | 4 (2-5) | 6 (4-7) | 4.5 (3-7) | .0002 |
| Prior HSCT, n (%) | 76 (56.7%) | 22 (44%) | 44 (64.7%) | 10 (62.5%) | .071 |
| Prior CAR, n (%) | 54 (40.3%) | 2 (4%) | 45 (66.2%) | 7 (43.8%) | <.0001 |
| Prior blinatumomab, n (%) | 44 (32.8%) | 4 (8%) | 28 (41.2%) | 12 (75%) | <.0001 |
| Prior inotuzumab, n (%) | 23 (17.2%) | 0 | 18 (26.5%) | 5 (31.3%) | .0002 |
| Disease status‡ | |||||
| No. of pts with ≥M2 marrow, % | 91 (67.9%) | 31 (62%) | 52 (76.5%) | 8 (50%) | .066 |
| No. of pts with CNS2+, % | 7 (5.2%) | 5 (10%) | 2 (2.9%) | 0 | .15 |
| No. of pts with EM§ disease, % | 24 (17.9%) | 4 (8%) | 12 (17.6%) | 8 (50%) | .0007 |
| Disease response‖ | |||||
| No. of pts with CR, % | 88 (66.2%) | 31 (62%) | 49 (73.1%) | 8 (50%) | .16 |
| No. of pts with MRD-neg CR, % | 77 (58.3%) | 27 (54%) | 42 (63.6%) | 8 (50%) | .45 |
CNS2+, CNS involvement with some degree of blasts on cytospin; EM, extramedullary; HSCT, hematopoietic stem cell transplant; MRD, minimal residual disease; pt, patient.
Age at consent.
Race total, n = 119; race was reported as unknown in 15 patients; non-White patients: African American, Asian, Hawaiian/Pacific Islander, and multirace.
Disease status before lymphodepleting chemotherapy.
EM disease refers to sites of EMD outside the CNS.
One patient was not evaluable for minimal residual disease (MRD) analysis because of inability to obtain aspirate sample, and another was not evaluable for CR or MRD owing to early death; CR (n = 133) and MRD (n = 132); both in the CD22 trial.